Quantbot Technologies LP Increases Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Quantbot Technologies LP lifted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 47.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 11,237 shares of the biopharmaceutical company’s stock after buying an additional 3,636 shares during the period. Quantbot Technologies LP’s holdings in Catalyst Pharmaceuticals were worth $235,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. abrdn plc acquired a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $10,115,000. Raymond James Financial Inc. acquired a new position in Catalyst Pharmaceuticals in the fourth quarter valued at $6,887,000. Skandinaviska Enskilda Banken AB publ grew its holdings in shares of Catalyst Pharmaceuticals by 74.3% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 731,900 shares of the biopharmaceutical company’s stock worth $15,421,000 after purchasing an additional 312,000 shares during the last quarter. Jane Street Group LLC increased its position in shares of Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after purchasing an additional 285,564 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at about $4,936,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $24.69 on Friday. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $26.16. The company has a market cap of $3.00 billion, a P/E ratio of 20.92, a PEG ratio of 3.31 and a beta of 0.84. The firm has a fifty day moving average of $22.66 and a two-hundred day moving average of $21.81.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares of the company’s stock, valued at $1,521,404.57. This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on CPRX shares. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Stephens reaffirmed an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Robert W. Baird lifted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Buy” and an average target price of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.